TLR7 and CD40 cooperate in IL-6 production via enhanced JNK and AP-1 activation

被引:54
作者
Bush, Tony J. Vanden [1 ]
Bishop, Gail A. [1 ,2 ]
机构
[1] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA
[2] Vet Assoc Med Ctr, Iowa City, IA USA
关键词
AP-1; B cells; CD40; JNK; TLR7;
D O I
10.1002/eji.200737602
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
During vaccination or infection, adaptive and innate immune receptors of B cells are engaged by microbial antigens/ligands. A better understanding of how innate and adaptive signaling pathways interact could enlighten B lymphocyte biology as well as aid immunotherapy strategies and vaccine design. To address this goal, we examined the effects of TLR stimulation on BCR and CD40-induced B cell activation. Synergistic production of IL-6 was observed in both human and mouse primary B cells stimulated through B cell antigen receptors, CD40 and TLR7, and these two receptors also cooperated independently of BCR signals. The enhanced IL-6 production was dependent upon the activity of c-Jun kinase (JNK) and cFos. Dual stimulation through CD40 and TLR7 markedly enhanced JNK activity. The increased level of active JNK in dual-stimulated cells was accompanied by an increase in the level of active AP-1 monomers cJun and cFos. The stimulation of B cells through both CD40 and TLR7 therefore enhanced the production of cytokines through increased JNK signaling and AP-1 activity. In addition, the dual stimulation increased cFos/AP-1 species in stimulated cells, effectively expanding the repertoire of AP-1 dimers as compared to singly stimulated B cells.
引用
收藏
页码:400 / 409
页数:10
相关论文
共 52 条
[41]   Tocilizumab: Blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders [J].
Paul-Pletzer, Kalanethee .
DRUGS OF TODAY, 2006, 42 (09) :559-576
[42]   Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells [J].
Ramakrishna, Venky ;
Vasilakos, John P. ;
Tario, Joseph D., Jr. ;
Berger, Marc A. ;
Wallace, Paul K. ;
Keler, Tibor .
JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5 (1)
[43]   c-Fos suppresses systemic inflammatory response to endotoxin [J].
Ray, N ;
Kuwahara, M ;
Takada, Y ;
Maruyama, K ;
Kawaguchi, T ;
Tsubone, H ;
Ishikawa, H ;
Matsuo, K .
INTERNATIONAL IMMUNOLOGY, 2006, 18 (05) :671-677
[44]   Heterogeneity of TLR-induced responses in dendritic cells: from innate to adaptive immunity [J].
Re, F ;
Strominger, JL .
IMMUNOBIOLOGY, 2004, 209 (1-2) :191-198
[45]   Toll-like receptors, endogenous ligands, and systemic autoimmune disease [J].
Rifkin, IR ;
Leadbetter, EA ;
Busconi, L ;
Viglianti, G ;
Marshak-Rothstein, A .
IMMUNOLOGICAL REVIEWS, 2005, 204 :27-42
[46]   TRANSCRIPTIONAL AUTO-REGULATION OF THE PROTO-ONCOGENE FOS [J].
SASSONECORSI, P ;
SISSON, JC ;
VERMA, IM .
NATURE, 1988, 334 (6180) :314-319
[47]   TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection [J].
Schlaepfer, Erika ;
Audige, Annette ;
Joller, Helene ;
Speck, Roberto F. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (05) :2888-2895
[48]   Interieukin-6: a new therapeutic target [J].
Smolen, Josef S. ;
Maini, Ravinder N. .
ARTHRITIS RESEARCH & THERAPY, 2006, 8 (Suppl 2)
[49]   CD40 ligand triggers interleukin-6 mediated B cell differentiation [J].
Urashima, M ;
Chauhan, D ;
Hatziyanni, M ;
Ogata, A ;
Hollenbaugh, D ;
Aruffo, A ;
Anderson, KC .
LEUKEMIA RESEARCH, 1996, 20 (06) :507-515
[50]   Adjuvant activities of immune response modifier R-848: Comparison with CpG ODN [J].
Vasilakos, JP ;
Smith, RMA ;
Gibson, SJ ;
Lindh, JM ;
Pederson, LK ;
Reiter, MJ ;
Smith, MH ;
Tomai, NA .
CELLULAR IMMUNOLOGY, 2000, 204 (01) :64-74